Skip to main content
SpringerLink
Log in

Therapeutic Advances in Biological Response Modifiers in the Treatment of Cutaneous T-Cell Lymphoma

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Cutaneous T-cell lymphoma (CTCL) is most often a skin-infiltrating malignancy of clonal CD4+ T-cells. Therapy is based on staging and the likelihood of progression. Biological response modifiers and chemotherapeutic agents are used to preserve the integrity of the host antitumour response while selectively targeting the malignant cells. The biological response-modifying treatment options currently used to treat CTCL are bexarotene, denileukin diftitox, interferon-α, interferon-γ and interleukin-12, as well as extracorporeal photopheresis and phototherapy. A combination therapy approach maximises response in patients with advanced CTCL. Biological response modifiers in combination with photopheresis are used for patients with the leukaemic phase of the disease. Among the majority of patients with advanced stage disease so treated, immune response augmentation appears to prolong survival. Future areas of research should assess not only survival and optimal treatment combinations, but also quality of life during the treatment period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996; 88: 2385–409

    CAS  PubMed  Google Scholar 

  2. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26–32

    Article  CAS  PubMed  Google Scholar 

  3. Vowels BR, Cassin M, Vonderheid E, et al. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90–4

    Article  CAS  PubMed  Google Scholar 

  4. Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132: 1309–13

    Article  CAS  PubMed  Google Scholar 

  5. Vonderheid EC, Tan ET, Kantor AF, et al. Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416–28

    Article  CAS  PubMed  Google Scholar 

  6. Kaye FJ, Bunn Jr PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784–90

    Article  CAS  PubMed  Google Scholar 

  7. Rook AH, Lessin SR, Jaworsky C, et al. Immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T-cells. Arch Dermatol 1993; 129: 486–9

    Article  CAS  PubMed  Google Scholar 

  8. Rook AH, Kubin M, Cassin M, et al. Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995; 154: 1491–8

    CAS  PubMed  Google Scholar 

  9. Peleman R, Wu J, Rargeas C, et al. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 1989; 170; 1751–6

    Article  CAS  PubMed  Google Scholar 

  10. D’Andrea A, Aste-Amea M, Valiante NM, et al. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–8

    Article  PubMed  Google Scholar 

  11. Boehm MF, Heyman RA, Nagpal S. A new generation of retinoid drugs for the treatment of dermatological disease. Emerg Drugs 1997; 2: 287–303

    Article  CAS  Google Scholar 

  12. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000; Jul-Aug: 1(4): 245–50

    Article  CAS  PubMed  Google Scholar 

  13. Sherman S, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340: 1075–9

    Article  CAS  PubMed  Google Scholar 

  14. Package insert, Targretin Gel, 1%. Ligand Pharmaceuticals

  15. Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997; 33: S34–6

    Article  CAS  PubMed  Google Scholar 

  16. Duvic M, Cather JC, Maize J, et al. DAB389IL-2 diphtheria fusion toxin reduces clinical responses in tumor stage cutaneous T-cell lymphoma. Am J Hematol 1998; 58: 78–90

    Article  Google Scholar 

  17. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Clin North Am 1995; 9: 1089–107

    CAS  Google Scholar 

  18. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alpha 2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395–407

    Article  CAS  PubMed  Google Scholar 

  19. Rook AH, Yoo EK, Grossman DJ, et al. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 1998; 10: 170–4

    Article  CAS  PubMed  Google Scholar 

  20. Knobler RM, Radaszkiewicz T. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa 2b and retinoids. J Am Acad Dermatol 1991; 24: 247–52

    Article  CAS  PubMed  Google Scholar 

  21. Dreno B, Celorier P, Litroux P. Roferon-A in combination with Tegason in cutaneous T-cell lymphomas. Acta Haematol 1993; 89 Suppl. 1: 28–32

    Article  Google Scholar 

  22. Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 203–7

    Article  CAS  PubMed  Google Scholar 

  23. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and with recombinant interferon alfa. J Am Acad Dermatol 1996; 35: 946–57

    Article  CAS  PubMed  Google Scholar 

  24. Fox FE, Niu Z, Lessin S, et al. Cytokine regulation of the growth of clonal malignant T-cells from patients with Sézary syndrome [abstract]. J Invest Dermatol 1997; 108: 552

    Article  Google Scholar 

  25. Gottlieb SL, Fox FE, Cassin M, et al. Interleukin 5 expression by peripheral blood mononuclear cells in Sézary syndrome correlates with peripheral eosinophilia and is suppressed by interferon alfa [abstract]. J Invest Dermatol 1995; 104: 683

    Google Scholar 

  26. Platsoucas CD, Fox FE, Oleszak E, et al. Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Res 1989; 9: 849–58

    CAS  Google Scholar 

  27. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferony for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208–12

    Article  CAS  PubMed  Google Scholar 

  28. Fox FE, Kubin M, Cassin M, et al. Retinoids synergize with interleukin-12 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1999; 19: 407–15

    Article  CAS  PubMed  Google Scholar 

  29. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 Therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902–8

    CAS  PubMed  Google Scholar 

  30. Rook AH, Foss F, Wood G, et al. A phase 2 open-label study reveals that recombinant human interleukin-12 (rhIL-12) is efficacious in patients with early stage cutaneous T-cell lymphoma (CTCL) [abstract]. J Invest Dermatol 2000; 114: 880

    Google Scholar 

  31. Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction by ultraviolet A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235–42

    Article  CAS  PubMed  Google Scholar 

  32. Rook AH, Suchin KR, Kao DMF, et al. Photopheresis: clinical applications and mechanisms of action. J Invest Dermatol Symp Proc 1999; 4: 85–9

    Article  CAS  Google Scholar 

  33. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracoporeal photopheresis in the management of patients with erythrodemic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43: 54–60

    Article  CAS  PubMed  Google Scholar 

  34. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257–63

    CAS  PubMed  Google Scholar 

  35. Ramsey DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1031–56

    Google Scholar 

  36. Clark C, Dawe RS, Evans AT, et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748–52

    Article  CAS  PubMed  Google Scholar 

  37. Suchin KR, DeNardo B, Macey W, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 15-year experience at a single institution. Pacific Dermatologic Association; 2000 Sep 13–17; Victoria, BC

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Pennsylvania School of Medicine, 3600, Spruce Street, 2 Maloney, Philadelphia, Pennsylvania, 19104, USA

    Carmela C. Vittorio, Alain H. Rook, Lars E. French, Michael Shapiro, Michael S. Lehrer & Jacqueline M. Junkins-Hopkins

Authors
  1. Carmela C. Vittorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alain H. Rook
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars E. French
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael S. Lehrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jacqueline M. Junkins-Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vittorio, C.C., Rook, A.H., French, L.E. et al. Therapeutic Advances in Biological Response Modifiers in the Treatment of Cutaneous T-Cell Lymphoma. BioDrugs 15, 431–437 (2001). https://doi.org/10.2165/00063030-200115070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115070-00002

Keywords

Search

Navigation